Drug intelligence / Profile preview

buparlisib + trametinib

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Buparlisib + trametinib is a combination therapy that targets two important signaling pathways in cancer cells. Buparlisib is a pan-class PI3K inhibitor that blocks the PI3K/AKT/mTOR pathway, while trametinib is a MEK inhibitor that blocks the MAPK pathway. This dual inhibition approach aims to overcome resistance mechanisms that can develop when either pathway is targeted alone. The combination has shown promising antitumor activity particularly in patients with KRAS-mutant ovarian cancer.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on buparlisib + trametinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on buparlisib + trametinib.

Explore the full profile